Petefészekrák: vizsgálatok itt: Argentína
10 trials · From ClinicalTrials.gov, checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Where
- Buenos Aires, Córdoba, Rosario, San Miguel de Tucumán
- Életkor
- 18 év and over
- People
- 420 worldwide
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500 - 3. fázisTaking peopleTorvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
- Where
- Buenos Aires, Capital Federal, Ciudad de Buenos Aires, Córdoba, Rosario, Salta, Santa Fe, Viedma
- Életkor
- 18 év and over
- People
- 950 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00 - 3. fázisTaking peopleMo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
- Where
- Buenos Aires, CABA, Ciudad Autonoma de Buenos Aire, Viedma
- Életkor
- 18 év and over
- People
- 720 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07694427 · EU 2025-523365-13-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Buenos Aires, Caba, Ciudad Autonoma Buenos Aires, Mar del Plata
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 3. fázisCsak meghívásosSafety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
- Where
- CABA, Córdoba, Rosario
- Életkor
- 18 év to 51 év
- People
- 250 worldwide
- Run by
- Tolmar Inc.
See details and how to joinNCT05645536 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Where
- Buenos Aires, CABA, Ciudad Autónoma de Buenos Aires, Córdoba, Mar del Plata, Rosario
- Életkor
- 18 év and over
- People
- 770 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00 - 3. fázisTaking peopleA Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Where
- Buenos Aires, CABA, Ciudad Autonoma de Buenos Aires, Ciudad Autónoma de Buenos Aires, La Rioja, Mar del Plata, Rosario
- Életkor
- 18 év and over
- People
- 900 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00 - No phaseTaking peopleStudy to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries
- Where
- Buenos Aires, Ciudad Autonoma de Buenos Aire
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- AbbVie
See details and how to joinNCT07539844 - No phaseNot yet taking people in ArgentínaMolecular Ovarian Cancer Assessment in LatiNoAmerican PAtients
- Where
- Buenos Aires, Rosario
- Életkor
- 18 év and over
- People
- 320 worldwide
- Run by
- Latin American Cooperative Oncology Group
See details and how to joinNCT07771400 - No phaseTaking peopleThe CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
- Where
- Rosario
- Életkor
- 40 év to 75 év
- People
- 6000 worldwide
- Run by
- Javier Toledo
See details and how to joinNCT06717295